The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F20%3A00116163" target="_blank" >RIV/00216224:14110/20:00116163 - isvavai.cz</a>
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1440-1681.13290" target="_blank" >https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1440-1681.13290</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/1440-1681.13290" target="_blank" >10.1111/1440-1681.13290</a>

Result language
angličtina
Original language name
The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure
Original language description
B-type natriuretic peptide (BNP) exhibits roles in natriuresis and diuresis, making it an ideal drug that may aid in diuresing a fluid-overloaded patient with poor or worsening renal function. Several randomized clinical trials have tested the hypothesis that infusions of pharmacological doses of BNP to acute heart failure (HF) patients may enhance decongestion and preserve renal function in this clinical setting. Unfortunately, none of these have demonstrated beneficial outcomes. The current challenge for BNP research in acute HF lies in addressing a failure of concept and a reluctance to abandon an ineffective research model. Future success will necessitate a detailed understanding of the mechanism of action of BNP, as well as better integration of basic and clinical science.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)